Mary Hitchcock Memorial Hosp
- Type
- Teaching hospital
- Where
- Lebanon, NH
- Medicare CCN
- 300003
- Received
- $2,974,739 in 767 records, 2020 ($219,862 general, $2,754,877 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 40 | $219,862 |
| 2020 | Research payment | 727 | $2,754,877 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 727 | $2,754,877 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 4 | $99,055 |
| Grant | 5 | $54,875 |
| Education | 15 | $25,320 |
| Space rental or facility fees (teaching hospital only) | 11 | $21,600 |
| Gift | 4 | $13,510 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 1 | $5,500 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Allergan, Inc. | $17,303 | Research payment | In-kind items and services | AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o | 2020 | |
| 2020-12-31 | Merck Sharp & Dohme LLC | $13,027 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-12-31 | AngioDynamics, Inc. | $13,000 | Education | In-kind items and services | Solero Device, Oncology Surgery | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $1,807 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Masimo Corporation | $880 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-31 | Allergan, Inc. | $600 | Research payment | In-kind items and services | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAF | 2020 | |
| 2020-12-31 | Masimo Corporation | $578 | Education | In-kind items and services | SedLine Device, Devices | 2020 | |
| 2020-12-31 | Masimo Corporation | $486 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-31 | Linvatec Corporation | $400 | Grant | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2020 | |
| 2020-12-31 | Masimo Corporation | $344 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-31 | AstraZeneca UK Limited | $235 | Research payment | In-kind items and services | This is an open label non randomised study designed to provide continued access to AZD1775 for eligible patients with ad | 2020 | |
| 2020-12-31 | Masimo Corporation | $172 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2020 | |
| 2020-12-31 | Masimo Corporation | $128 | Education | In-kind items and services | EMMA and ISA Device, Devices | 2020 | |
| 2020-12-31 | Masimo Corporation | $95 | Education | In-kind items and services | SedLine Device, Devices | 2020 | |
| 2020-12-30 | KARL STORZ Endoscopy-America | $81,167 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2020 | ||
| 2020-12-29 | ABBVIE INC. | $2,100 | Research payment | Cash or cash equivalent | M16-063 | 2020 | |
| 2020-12-29 | ABBVIE INC. | $1,000 | Research payment | Cash or cash equivalent | M16-063 | 2020 | |
| 2020-12-24 | Medical Device Business Services, Inc. | $100 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $2,309 | Research payment | Cash or cash equivalent | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2020 | |
| 2020-12-23 | Allergan, Inc. | $1,068 | Research payment | Cash or cash equivalent | AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o | 2020 | |
| 2020-12-21 | ABBVIE INC. | $4,784 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M13-542 | 2020 |
| 2020-12-21 | Gilead Sciences, Inc. | $1,048 | Research payment | Cash or cash equivalent | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2020 | |
| 2020-12-21 | ABBVIE INC. | $80 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M13-542 | 2020 |
| 2020-12-21 | ABBVIE INC. | $80 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-555 | 2020 |
| 2020-12-21 | ABBVIE INC. | $80 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-555 | 2020 |
| 2020-12-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-18 | Medical Device Business Services, Inc. | $409 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2020 |
| 2020-12-18 | Medtronic USA, Inc. | $98 | Research payment | Cash or cash equivalent | VISUALASE Device, MRI-guided laser ablation | SLATE | 2020 |
| 2020-12-18 | Medical Device Business Services, Inc. | $50 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01 Master Study A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab | 2020 |
| 2020-12-17 | E.R. Squibb & Sons, L.L.C. | $8,200 | Research payment | Cash or cash equivalent | ORENCIA Biological, Immunology | Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy | 2020 |
| 2020-12-17 | Boehringer Ingelheim Limited | $69 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2020 |
| 2020-12-16 | ABBVIE INC. | $1,919 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M13-542 | 2020 |
| 2020-12-16 | Incyte Corporation | $1,118 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-16 | Incyte Corporation | $40 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-15 | GlaxoSmithKline, LLC. | $11,544 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB | 2020 | |
| 2020-12-15 | ABBVIE INC. | $2,981 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-555 | 2020 |
| 2020-12-15 | Allergan, Inc. | $1,948 | Research payment | Cash or cash equivalent | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAF | 2020 | |
| 2020-12-15 | Ferring International Pharmascience Center US | $1,507 | Research payment | Cash or cash equivalent | A Multi-Center, Randomized, Pivotal Study Evaluating?AMPLEX?Compared To Autogenous Bone Graft in Subjects Indicated for | 2020 | |
| 2020-12-14 | Bayer Healthcare Pharmaceuticals Inc. | $660 | Research payment | Cash or cash equivalent | Non-Covered | BAY 1841788 mHSPC | 2020 |
| 2020-12-11 | Aesculap Implant Systems, LLC | $12,144 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-11 | W. L. Gore & Associates, Inc. | $3,776 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | TAMBE - Initial Feasibility Assessment of the GORE EXCLUDER Juxtarenal and Thoracoabcominal Branch System in the Treatme | 2020 |
| 2020-12-11 | Celgene Corporation | $2,577 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single | 2020 |
| 2020-12-11 | W. L. Gore & Associates, Inc. | $350 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararena | 2020 |
| 2020-12-08 | Biofrontera Inc. | $1,500 | Research payment | Cash or cash equivalent | AMELUZ Drug, DERMATOLOGY | SPLIT FACE PHOTODYNAMIC THERAPY ADDING RED LIGHT EXPOSURE TO DAYLIGHT PDT | 2020 |
| 2020-12-08 | Genentech, Inc. | $892 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY | 2020 |
| 2020-12-08 | Medical Device Business Services, Inc. | $409 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2020 |
| 2020-12-08 | GlaxoSmithKline, LLC. | $200 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB | 2020 | |
| 2020-12-08 | Medical Device Business Services, Inc. | $150 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2020 |
| 2020-12-08 | Medical Device Business Services, Inc. | $50 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2020 |
| 2020-12-07 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SFA DES PIVOTAL | 2020 |
| 2020-12-07 | Bayer Healthcare Pharmaceuticals Inc. | $969 | Research payment | Cash or cash equivalent | Mirena Drug, Women's Health | BAY86-5028 Mirena extension contraception | 2020 |
| 2020-12-07 | Gilead Sciences, Inc. | $520 | Research payment | Cash or cash equivalent | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2020 | |
| 2020-12-04 | Medical Device Business Services, Inc. | $1,820 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2020 |
| 2020-12-04 | W. L. Gore & Associates, Inc. | $1,500 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararena | 2020 |
| 2020-12-04 | W. L. Gore & Associates, Inc. | $1,500 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG TSSB-LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | 2020 |
| 2020-12-03 | Merck Sharp & Dohme LLC | $778 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01Substudy 2 A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrol | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-01 | Vascular Graft Solutions Inc | $82,178 | Research payment | Cash or cash equivalent | VEST Device | VEST Venous Graft External Support Pivotal Study | 2020 |
| 2020-12-01 | Boehringer Ingelheim International GmbH | $63 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2020 |
| 2020-11-30 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-11-30 | Merck Sharp & Dohme LLC | $365 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-11-30 | Merck Sharp & Dohme LLC | $339 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-11-23 | Genentech, Inc. | $18,970 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | TECENTRIQ PLUS AVASTIN FOLLOWING CURATIVE RESECTION IN PATIENTS AT HIGH RISK OF RECURRENCE | 2020 |
| 2020-11-23 | Medtronic USA, Inc. | $1,215 | Research payment | Cash or cash equivalent | VISUALASE Device, MRI-guided laser ablation | SLATE | 2020 |
| 2020-11-23 | GlaxoSmithKline, LLC. | $250 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB | 2020 | |
| 2020-11-23 | ABBVIE INC. | $160 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-555 | 2020 |
| 2020-11-20 | Amgen Inc. | $8,869 | Research payment | Cash or cash equivalent | GALACTIC - HF | 2020 | |
| 2020-11-19 | Boston Scientific Corporation | $1,500 | Research payment | Cash or cash equivalent | EKOSONIC Device, PERIPHERAL VASCULAR | KNOCOUT PE | 2020 |
| 2020-11-19 | Boston Scientific Corporation | $1,482 | Research payment | Cash or cash equivalent | EKOSONIC Device, PERIPHERAL VASCULAR | KNOCOUT PE | 2020 |
| 2020-11-19 | ABBVIE INC. | $80 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M13-542 | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $6,744 | Research payment | Cash or cash equivalent | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2020 | |
| 2020-11-17 | Boston Scientific Corporation | $20,000 | Grant | Cash or cash equivalent | GENERAL - STRUCTURAL HEART Device, STRUCTURAL HEART | 2020 | |
| 2020-11-17 | Genentech, Inc. | $19,190 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | LCMC3 | 2020 |
| 2020-11-17 | Allergan, Inc. | $2,618 | Research payment | Cash or cash equivalent | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAF | 2020 | |
| 2020-11-17 | ABBVIE INC. | $1,490 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-555 | 2020 |
| 2020-11-17 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-11-16 | Covidien LP | $10,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-16 | Genentech, Inc. | $2,630 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY | 2020 |
| 2020-11-16 | ABBVIE INC. | $1,919 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M13-542 | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-11 | Incyte Corporation | $2,795 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-11-11 | Incyte Corporation | $2,500 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-11-11 | Incyte Corporation | $1,500 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-11-11 | Gilead Sciences, Inc. | $455 | Research payment | Cash or cash equivalent | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2020 | |
| 2020-11-11 | Incyte Corporation | $20 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-11-10 | SANOFI PASTEUR INC. | $18,285 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2020 | |
| 2020-11-10 | Genentech, Inc. | $1,404 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | LCMC3 | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-11-06 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2020 | |
| 2020-11-06 | Boston Scientific Corporation | $221 | Research payment | Cash or cash equivalent | EKOSONIC Device, PERIPHERAL VASCULAR | KNOCOUT PE | 2020 |
| 2020-11-05 | Takeda Pharmaceuticals U.S.A., Inc. | $39,673 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2020 | |
| 2020-11-05 | Genentech, Inc. | $5,460 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | 1L MTNBC IPATASERTIB TECENTRIQ PACLITAXEL | 2020 |
| 2020-11-05 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,708 | Research payment | Cash or cash equivalent | ILUMYA Biological, Dermatology | A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psor | 2020 |
| 2020-11-05 | GlaxoSmithKline, LLC. | $2,150 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB | 2020 | |
| 2020-11-05 | SUN PHARMACEUTICAL INDUSTRIES INC. | $130 | Research payment | Cash or cash equivalent | ILUMYA Biological, Dermatology | A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psor | 2020 |
| 2020-11-03 | Genentech, Inc. | $15,439 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | LCMC3 | 2020 |
| 2020-11-01 | Boehringer Ingelheim International GmbH | $62 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2020 |
| 2020-10-30 | Incyte Corporation | $1,500 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-30 | Incyte Corporation | $500 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-30 | MicroVention, Inc. | $489 | Research payment | Cash or cash equivalent | CASPER Device, Neurological Product | CONFIDENCE | 2020 |
| 2020-10-30 | W. L. Gore & Associates, Inc. | $100 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2020 |
| 2020-10-30 | W. L. Gore & Associates, Inc. | $57 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG TSSB-LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | 2020 |
| 2020-10-29 | Masimo Corporation | $67 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-10-28 | Gilead Sciences, Inc. | $723 | Research payment | Cash or cash equivalent | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2020 | |
| 2020-10-28 | SUN PHARMACEUTICAL INDUSTRIES INC. | $130 | Research payment | Cash or cash equivalent | ILUMYA Biological, Dermatology | A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psor | 2020 |
| 2020-10-27 | ABBVIE INC. | $2,981 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-555 | 2020 |
| 2020-10-27 | Eli Lilly and Company | $134 | Research payment | In-kind items and services | MONARCH 2- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FULVESTRANT WITH OR WITHOUT ABEMACICLIB, A C | 2020 | |
| 2020-10-26 | Genentech, Inc. | $2,523 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-10-26 | ABBVIE INC. | $1,510 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M13-542 | 2020 |
| 2020-10-26 | ABBVIE INC. | $177 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M13-542 | 2020 |
| 2020-10-26 | ABBVIE INC. | $160 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-555 | 2020 |
| 2020-10-26 | NEUROPACE, INC. | $70 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2020 |
| 2020-10-26 | NEUROPACE, INC. | $66 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2020 |
| 2020-10-26 | NEUROPACE, INC. | $66 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2020 |
| 2020-10-26 | NEUROPACE, INC. | $66 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2020 |
| 2020-10-26 | NEUROPACE, INC. | $66 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2020 |
| 2020-10-26 | NEUROPACE, INC. | $66 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2020 |
| 2020-10-26 | NEUROPACE, INC. | $66 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2020 |
| 2020-10-26 | NEUROPACE, INC. | $66 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2020 |
| 2020-10-26 | NEUROPACE, INC. | $66 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2020 |
| 2020-10-26 | NEUROPACE, INC. | $66 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2020 |
| 2020-10-22 | Medtronic Vascular, Inc. | $20,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-10-22 | Incyte Corporation | $6,500 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-22 | Ferring International Pharmascience Center US | $5,200 | Research payment | Cash or cash equivalent | A Multi-Center, Randomized, Pivotal Study Evaluating?AMPLEX?Compared To Autogenous Bone Graft in Subjects Indicated for | 2020 | |
| 2020-10-22 | Incyte Corporation | $3,793 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-22 | Incyte Corporation | $3,500 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-22 | Incyte Corporation | $2,600 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-22 | Incyte Corporation | $2,600 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-22 | Incyte Corporation | $1,560 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-22 | Astellas Pharma Global Development | $1,500 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED STUDY OF ENZALUTAMIDE IN PATIENTS WITH LOCALIZED PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE (ENACT) | 2020 |
| 2020-10-22 | Incyte Corporation | $650 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-22 | Incyte Corporation | $390 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-22 | Boston Scientific Corporation | $221 | Research payment | Cash or cash equivalent | EKOSONIC Device, PERIPHERAL VASCULAR | KNOCOUT PE | 2020 |
| 2020-10-21 | Gilead Sciences, Inc. | $6,779 | Research payment | Cash or cash equivalent | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2020 | |
| 2020-10-21 | Smith+Nephew, Inc. | $159 | Gift | In-kind items and services | Other VideoArthroscopes Device, Sports Med Visualization | 2020 | |
| 2020-10-19 | Genentech, Inc. | $1,295 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2020 |
| 2020-10-19 | Allergan, Inc. | $1,121 | Research payment | Cash or cash equivalent | AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o | 2020 | |
| 2020-10-19 | Boston Scientific Corporation | $950 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SFA DES PIVOTAL | 2020 |
| 2020-10-19 | Gilead Sciences, Inc. | $845 | Research payment | Cash or cash equivalent | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2020 | |
| 2020-10-19 | GlaxoSmithKline, LLC. | $100 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB | 2020 | |
| 2020-10-16 | MicroVention, Inc. | $1,500 | Research payment | Cash or cash equivalent | CASPER Device, Neurological Product | CONFIDENCE | 2020 |
| 2020-10-15 | Takeda Pharmaceuticals U.S.A., Inc. | $8,450 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2020 | |
| 2020-10-15 | Smith+Nephew, Inc. | $767 | Gift | In-kind items and services | LENS 4K Device, Sports Med Visualization | 2020 | |
| 2020-10-15 | Smith+Nephew, Inc. | $439 | Gift | In-kind items and services | LENS 4K Device, Sports Med Visualization | 2020 | |
| 2020-10-08 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,500 | Research payment | Cash or cash equivalent | ILUMYA Biological, Dermatology | A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psor | 2020 |
| 2020-10-08 | Incyte Corporation | $26 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-08 | Incyte Corporation | $16 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-08 | Incyte Corporation | $16 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-08 | Incyte Corporation | $16 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-08 | Incyte Corporation | $16 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-08 | Incyte Corporation | $16 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-08 | Incyte Corporation | $16 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-10-07 | Genentech, Inc. | $23,205 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | 1L MTNBC IPATASERTIB TECENTRIQ PACLITAXEL | 2020 |
| 2020-10-07 | GlaxoSmithKline, LLC. | $15,304 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB | 2020 | |
| 2020-10-07 | ABBVIE INC. | $962 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-555 | 2020 |
| 2020-10-04 | Genentech, Inc. | $2,500 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | 1L MTNBC IPATASERTIB TECENTRIQ PACLITAXEL | 2020 |
| 2020-10-02 | W. L. Gore & Associates, Inc. | $11,391 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararena | 2020 |
| 2020-10-02 | W. L. Gore & Associates, Inc. | $520 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararena | 2020 |
| 2020-10-02 | Allergan, Inc. | $38 | Research payment | Cash or cash equivalent | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAF | 2020 | |
| 2020-10-01 | Abbott Laboratories | $5,255 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | ABSORB III Randomized Controlled Trial (RCT) (ABSORB-III) | 2020 |
| 2020-10-01 | Genentech, Inc. | $1,562 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | A PHASE III STUDY IN COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN BRAFWT MELANOMA PATIENTS | 2020 |
| 2020-10-01 | Genentech, Inc. | $1,295 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2020 |
| 2020-10-01 | Allergan, Inc. | $500 | Research payment | Cash or cash equivalent | AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o | 2020 | |
| 2020-10-01 | Boehringer Ingelheim International GmbH | $62 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2020 |
| 2020-09-30 | Intuitive Surgical, Inc. | $1,807 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-09-29 | Eisai Inc. | $2,600 | Research payment | Cash or cash equivalent | Halaven Drug, Oncology | An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combi | 2020 |
| 2020-09-29 | Eisai Inc. | $2,600 | Research payment | Cash or cash equivalent | Halaven Drug, Oncology | An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combi | 2020 |
| 2020-09-29 | Eisai Inc. | $2,600 | Research payment | Cash or cash equivalent | Halaven Drug, Oncology | An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combi | 2020 |
| 2020-09-28 | ABBVIE INC. | $5,265 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-555 | 2020 |
| 2020-09-25 | W. L. Gore & Associates, Inc. | $8,285 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararena | 2020 |
| 2020-09-25 | SEAGEN INC. | $5,200 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-09-25 | ABBVIE INC. | $3,020 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M13-542 | 2020 |
| 2020-09-24 | AstraZeneca UK Limited | $7,630 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2020 | |
| 2020-09-24 | AstraZeneca UK Limited | $2,107 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2020 | |
| 2020-09-24 | Merck Sharp & Dohme LLC | $226 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01Substudy 1 A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combi | 2020 |
| 2020-09-24 | Boehringer Ingelheim Limited | $11 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $5,123 | Research payment | Cash or cash equivalent | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2020 | |
| 2020-09-23 | Genentech, Inc. | $2,453 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY | 2020 |
| 2020-09-23 | SUN PHARMACEUTICAL INDUSTRIES INC. | $428 | Research payment | Cash or cash equivalent | ILUMYA Biological, Dermatology | A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psor | 2020 |
| 2020-09-23 | Genentech, Inc. | $29 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY | 2020 |
| 2020-09-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,673 | Research payment | Cash or cash equivalent | OFEV Drug, RESPIRATORY | Nintedanib in PF ILD extension | 2020 |
The latest 200 records of 767.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Lebanon, NH, county Grafton County, NH, state New Hampshire; placed by its city name.
| Measure | Place (city or town) Lebanon, NH | County Grafton County, NH | State New Hampshire |
|---|---|---|---|
| Population B01003 | 14,999 | 92,120 | 1,394,868 |
| Population, 2020 census P1 | 14,282 | 91,118 | 1,377,529 |
| Median age B01002 | 38.9 | 44.1 | 43.3 |
| Under 18 B01001 | 14.6% | 15.6% | 18.2% |
| 65 and over B01001 | 21.4% | 23.0% | 20.1% |
| Households B11001 | 6,917 | 37,107 | 555,822 |
| Foreign born B05002 | 8.6% | 5.6% | 6.1% |
| Median household income B19013 | $98,147 | $88,261 | $99,031 |
| Median family income B19113 | $120,046 | $109,351 | $122,715 |
| Per capita income B19301 | $56,599 | $52,790 | $52,798 |
| Poverty rate B17001 | 7.0% | 10.4% | 7.2% |
| Unemployment rate B23025 | 0.8% | 3.2% | 3.3% |
| Civilian labor force B23025 | 9,352 | 48,140 | 775,826 |
| Mean commute (minutes) B08013 | 14.0 | 22.2 | 26.7 |
| Bachelor's degree or higher B15003 | 57.5% | 46.7% | 40.6% |
| Housing units B25001 | 7,855 | 51,920 | 648,472 |
| Owner-occupied B25003 | 51.2% | 71.3% | 72.8% |
| Renters B25003 | 48.8% | 28.7% | 27.2% |
| Median home value B25077 | $385,400 | $344,500 | $402,500 |
| Median gross rent B25064 | $1,744 | $1,301 | $1,491 |
| White, not Hispanic B03002 | 84.3% | 87.5% | 86.9% |
| Black B03002 | 0.7% | 1.1% | 1.3% |
| Hispanic or Latino B03002 | 3.1% | 2.9% | 4.7% |
| Asian B03002 | 6.7% | 3.5% | 2.6% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Lebanon, NH.
Comments